PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
8.54%
Cost growth of 8.54% while RVPH maintains flat costs. Bruce Berkowitz would investigate efficiency gap.
-83.05%
Gross profit decline while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-18.94%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
28.45%
G&A growth 50-75% of RVPH's 41.40%. Bruce Berkowitz would examine operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-7.93%
Both companies reducing total costs. Martin Whitman would check industry trends.
-100.00%
Interest expense reduction while RVPH shows 117.08% growth. Joel Greenblatt would examine advantage.
8.54%
D&A growth while RVPH reduces D&A. John Neff would investigate differences.
7.52%
EBITDA growth below 50% of RVPH's 20.93%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
7.21%
Operating income growth below 50% of RVPH's 20.69%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-9.03%
Other expenses reduction while RVPH shows 91.10% growth. Joel Greenblatt would examine advantage.
7.01%
Pre-tax income growth below 50% of RVPH's 23.67%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-68.42%
Tax expense reduction while RVPH shows 261.41% growth. Joel Greenblatt would examine advantage.
7.01%
Net income growth below 50% of RVPH's 23.56%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
8.82%
EPS change of 8.82% while RVPH is flat. Bruce Berkowitz would examine quality.
8.82%
Diluted EPS change of 8.82% while RVPH is flat. Bruce Berkowitz would examine quality.
0.91%
Share count change of 0.91% while RVPH is stable. Bruce Berkowitz would verify approach.
0.91%
Diluted share change of 0.91% while RVPH is stable. Bruce Berkowitz would verify approach.